BIOTECH'S LOST ARCHIVE

Summary from the TLDR newsletter

FDA submissions contain unparalleled details about the design of clinical trials, manufacturing processes, safety assessments, and reviewer correspondences, but this information is not publicly available. This article details a proposal for a legally grounded mechanism for democratizing FDA filings. Freeing FDA submissions from obscurity would level the playing field for small biotech firms, academic teams, and nonprofits and enable AI-driven regulatory intelligence tools that dramatically lower compliance costs and accelerate approval timelines. AI stands to revolutionize drug development, but only if it can be trained on high-quality unredacted datasets.